VX-118 / Vertex - LARVOL DELTA

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=225 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | N=159 ➔ 225 | Trial completion date: Apr 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed

Trial completion • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting

Enrollment closed • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases